EGFR Mutation Subtype and Risk of Brain Metastases From Non-Small Cell Lung Cancer in the Osimertinib Era: EGFR Subtype and Brain Metastases in NSCLC.
Differences in brain metastasis development between EGFR L858R and Ex19Del mutations appeared to be mitigated among patients undergoing osimertinib compared with early-generation TKIs, representing an important systems bioengineering approach.